Hepatitis C Management: A Flu-Fighting Berry
Armed with elderberry, those with Hepatitis C have a helpful tool to persevere through this cold and flu season.
Continue reading »Armed with elderberry, those with Hepatitis C have a helpful tool to persevere through this cold and flu season.
Continue reading »A French trial shows that triple Hepatitis C therapy can be successful in those who have liver disease that has already advanced to cirrhosis.
Continue reading »A first-in-class medical device that helps clear Hepatitis C from the blood, the Hemopurifier® will be part of a compassionate-use program for previous Hepatitis C non-responders or relapsers in India.
Continue reading »It is possible to enjoy a holiday feast without the resulting food coma and accompanying liver aggravation that can be harmful with Hepatitis C.
Continue reading »Following a mid-stage study showing extremely high cure rates, the Phase III trial for Abbott's direct acting antiviral drugs are now recruiting participants with Hepatitis C genotype 1.
Continue reading »In combination with interferon and ribavirin, Biotron's experimental drug, BIT225, is now being tested in a Phase II trial for those co-infected with Hepatitis C and HIV.
Continue reading »A pre-clinical study demonstrated Inovio's synthetic Hepatitis B therapeutic vaccine capable of eliminating this destructive virus in the liver.
Continue reading »In a mid-stage trial, Abbott's all-oral drug combo for Hepatitis C posted cure rates in the 90th percentile - even in previous non-responders.
Continue reading »A component of many Hepatitis C treatment programs, boceprevir has just received an update to its package insert on adverse events.
Continue reading »Vertex's VX-135 is being paired with Medivir and Janssen's simeprevir in an all-oral Phase II Hepatitis C trial.
Continue reading »You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window